The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

A dopa decarboxylase inhibitor (DDCI), such as carbidopa or benserazide, is administered with levodopa to attenuate its peripheral conversion to dopamine, reduce nausea and increase central ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced drug delivery systems, today announced the ...

but a press release (2/24/09) indicated that: "the time to dyskinesia was statistically significantly shorter in Stalevo-treated patients compared with carbidopa/levodopa-treated patients".

Laxxon's LXM.5 can achieve such improved bioavailability and levodopa levels due to the sequential release of the levodopa and carbidopa compounds. Laxxon was granted the patent for sequential ...

Gocovri (amantadine) is an extended-release version of amantadine prescribed alongside levodopa to improve movement. Nourianz ...